Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 228

1.

Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients.

Ooft SN, Weeber F, Dijkstra KK, McLean CM, Kaing S, van Werkhoven E, Schipper L, Hoes L, Vis DJ, van de Haar J, Prevoo W, Snaebjornsson P, van der Velden D, Klein M, Chalabi M, Boot H, van Leerdam M, Bloemendal HJ, Beerepoot LV, Wessels L, Cuppen E, Clevers H, Voest EE.

Sci Transl Med. 2019 Oct 9;11(513). pii: eaay2574. doi: 10.1126/scitranslmed.aay2574.

PMID:
31597751
2.

Factors influencing long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei originating from appendiceal neoplasms.

van Eden WJ, Kok NFM, Snaebjornsson P, Jóźwiak K, Woensdregt K, Bottenberg PD, Boot H, Aalbers AGJ.

BJS Open. 2019 Feb 19;3(3):376-386. doi: 10.1002/bjs5.50134. eCollection 2019 Jun.

3.

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II).

Koemans WJ, van der Kaaij RT, Boot H, Buffart T, Veenhof AAFA, Hartemink KJ, Grootscholten C, Snaebjornsson P, Retel VP, van Tinteren H, Vanhoutvin S, van der Noort V, Houwink A, Hahn C, Huitema ADR, Lahaye M, Los M, van den Barselaar P, Imhof O, Aalbers A, van Dam GM, van Etten B, Wijnhoven BPL, Luyer MDP, Boerma D, van Sandick JW.

BMC Cancer. 2019 May 6;19(1):420. doi: 10.1186/s12885-019-5640-2.

4.

Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6)

Rovers KP, Bakkers C, Simkens GAAM, Burger JWA, Nienhuijs SW, Creemers GM, Thijs AMJ, Brandt-Kerkhof ARM, Madsen EVE, Ayez N, de Boer NL, van Meerten E, Tuynman JB, Kusters M, Sluiter NR, Verheul HMW, van der Vliet HJ, Wiezer MJ, Boerma D, Wassenaar ECE, Los M, Hunting CB, Aalbers AGJ, Kok NFM, Kuhlmann KFD, Boot H, Chalabi M, Kruijff S, Been LB, van Ginkel RJ, de Groot DJA, Fehrmann RSN, de Wilt JHW, Bremers AJA, de Reuver PR, Radema SA, Herbschleb KH, van Grevenstein WMU, Witkamp AJ, Koopman M, Haj Mohammad N, van Duyn EB, Mastboom WJB, Mekenkamp LJM, Nederend J, Lahaye MJ, Snaebjornsson P, Verhoef C, van Laarhoven HWM, Zwinderman AH, Bouma JM, Kranenburg O, van 't Erve I, Fijneman RJA, Dijkgraaf MGW, Hemmer PHJ, Punt CJA, Tanis PJ, de Hingh IHJT; Dutch Peritoneal Oncology Group (DPOG); Dutch Colorectal Cancer Group (DCCG).

BMC Cancer. 2019 Apr 25;19(1):390. doi: 10.1186/s12885-019-5545-0.

5.

Long-term survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with peritoneal metastases of urachal cancer.

Mertens LS, Behrendt MA, Mehta AM, Stokkel L, de Jong J, Boot H, Horenblas S, van der Heijden MS, Moonen LM, Aalbers AGJ, Meinhardt W, van Rhijn BWG.

Eur J Surg Oncol. 2019 Sep;45(9):1740-1744. doi: 10.1016/j.ejso.2019.03.034. Epub 2019 Apr 1.

PMID:
31003721
6.

CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.

Slagter AE, Jansen EPM, van Laarhoven HWM, van Sandick JW, van Grieken NCT, Sikorska K, Cats A, Muller-Timmermans P, Hulshof MCCM, Boot H, Los M, Beerepoot LV, Peters FPJ, Hospers GAP, van Etten B, Hartgrink HH, van Berge Henegouwen MI, Nieuwenhuijzen GAP, van Hillegersberg R, van der Peet DL, Grabsch HI, Verheij M.

BMC Cancer. 2018 Sep 10;18(1):877. doi: 10.1186/s12885-018-4770-2.

7.

[A woman with fever and a painful hip].

Boot H, Savelkoul C, Tjan DHT.

Ned Tijdschr Geneeskd. 2018 Jun 22;162. pii: D2260. Dutch.

PMID:
30040257
8.

Effect of Hospital Volume With Respect to Performing Gastric Cancer Resection on Recurrence and Survival: Results From the CRITICS Trial.

Claassen YHM, van Amelsfoort RM, Hartgrink HH, Dikken JL, de Steur WO, van Sandick JW, van Grieken NCT, Cats A, Boot H, Trip AK, Jansen EPM, Kranenbarg EM, Braak JPBM, Putter H, Henegouwen MIVB, Verheij M, van de Velde CJH.

Ann Surg. 2019 Dec;270(6):1096-1102. doi: 10.1097/SLA.0000000000002940.

PMID:
29995679
9.

Association between hospital volume and quality of gastric cancer surgery in the CRITICS trial.

Claassen YHM, van Sandick JW, Hartgrink HH, Dikken JL, De Steur WO, van Grieken NCT, Boot H, Cats A, Trip AK, Jansen EPM, Meershoek-Klein Kranenbarg WM, Braak JPBM, Putter H, van Berge Henegouwen MI, Verheij M, van de Velde CJH.

Br J Surg. 2018 May;105(6):728-735. doi: 10.1002/bjs.10773.

PMID:
29652082
10.

Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.

Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek-Klein Kranenbarg E, Boot H, Trip AK, Swellengrebel HAM, van Laarhoven HWM, Putter H, van Sandick JW, van Berge Henegouwen MI, Hartgrink HH, van Tinteren H, van de Velde CJH, Verheij M; CRITICS investigators.

Lancet Oncol. 2018 May;19(5):616-628. doi: 10.1016/S1470-2045(18)30132-3. Epub 2018 Apr 9.

PMID:
29650363
11.

Phase I study of combined indomethacin and platinum-based chemotherapy to reduce platinum-induced fatty acids.

van der Velden DL, Cirkel GA, Houthuijzen JM, van Werkhoven E, Roodhart JML, Daenen LGM, Kaing S, Gerrits J, Verhoeven-Duif NM, Grootscholten C, Boot H, Sessa C, Bloemendal HJ, De Vos FY, Voest EE.

Cancer Chemother Pharmacol. 2018 May;81(5):911-921. doi: 10.1007/s00280-018-3563-2. Epub 2018 Mar 24.

PMID:
29574584
12.

Using textbook outcome as a measure of quality of care in oesophagogastric cancer surgery.

van der Kaaij RT, de Rooij MV, van Coevorden F, Voncken FEM, Snaebjornsson P, Boot H, van Sandick JW.

Br J Surg. 2018 Apr;105(5):561-569. doi: 10.1002/bjs.10729. Epub 2018 Feb 21.

PMID:
29465746
13.

Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.

van Eden WJ, Kok NFM, Woensdregt K, Huitema ADR, Boot H, Aalbers AGJ.

Eur J Surg Oncol. 2018 Feb;44(2):220-227. doi: 10.1016/j.ejso.2017.10.216. Epub 2017 Nov 15.

PMID:
29258720
14.

Feasibility and effectiveness of trifluridine/tipiracil in metastatic colorectal cancer: real-life data from The Netherlands.

Kwakman JJM, Vink G, Vestjens JH, Beerepoot LV, de Groot JW, Jansen RL, Opdam FL, Boot H, Creemers GJ, van Rooijen JM, Los M, Vulink AJE, Schut H, van Meerten E, Baars A, Hamberg P, Kapiteijn E, Sommeijer DW, Punt CJA, Koopman M.

Int J Clin Oncol. 2018 Jun;23(3):482-489. doi: 10.1007/s10147-017-1220-0. Epub 2017 Dec 4.

15.

Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study.

van der Kaaij RT, Braam HJ, Boot H, Los M, Cats A, Grootscholten C, Schellens JH, Aalbers AG, Huitema AD, Knibbe CA, Boerma D, Wiezer MJ, van Ramshorst B, van Sandick JW.

JMIR Res Protoc. 2017 Jul 13;6(7):e136. doi: 10.2196/resprot.7790.

16.

Timing of Systemic Chemotherapy in Patients With Colorectal Peritoneal Carcinomatosis Treated With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.

van Eden WJ, Kok NF, Jóźwiak K, Lahaye ML, Beets GL, van Leerdam ME, Boot H, Aalbers AG.

Dis Colon Rectum. 2017 May;60(5):477-487. doi: 10.1097/DCR.0000000000000774.

PMID:
28383447
17.

Survival of patients with colorectal peritoneal metastases is affected by treatment disparities among hospitals of diagnosis: A nationwide population-based study.

Rovers KP, Simkens GA, Vissers PA, Lemmens VE, Verwaal VJ, Bremers AJ, Wiezer MJ, Burger JW, Hemmer PH, Boot H, van Grevenstein WM, Meijerink WJ, Aalbers AG, Punt CJ, Tanis PJ, de Hingh IH; Dutch Peritoneal Oncology Group (DPOG).

Eur J Cancer. 2017 Apr;75:132-140. doi: 10.1016/j.ejca.2016.12.034. Epub 2017 Feb 20.

PMID:
28222307
18.

Human epididymis protein 4 immunostaining of malignant ascites differentiates cancer of Müllerian origin from gastrointestinal cancer.

Stiekema A, Van de Vijver KK, Boot H, Broeks A, Korse CM, van Driel WJ, Kenter GG, Lok CA.

Cancer Cytopathol. 2017 Mar;125(3):197-204. doi: 10.1002/cncy.21811. Epub 2017 Feb 15.

19.

Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients.

Kwakman JJM, Baars A, Boot H, Pruijt JFM, Winther SB, Pfeiffer P, Punt CJA.

Acta Oncol. 2017 Jul;56(7):1023-1026. doi: 10.1080/0284186X.2016.1278459. Epub 2017 Jan 19. No abstract available.

PMID:
28102094
20.

Correlation between viral load, multiplicity of infection, and persistence of HPV16 and HPV18 infection in a Dutch cohort of young women.

van der Weele P, van Logchem E, Wolffs P, van den Broek I, Feltkamp M, de Melker H, Meijer CJ, Boot H, King AJ.

J Clin Virol. 2016 Oct;83:6-11. doi: 10.1016/j.jcv.2016.07.020. Epub 2016 Aug 4.

PMID:
27522635
21.

Correction: Genetic Diversity in the Major Capsid L1 Protein of HPV-16 and HPV-18 in the Netherlands.

King AJ, Sonsma JA, Vriend HJ, van der Sande MA, Feltkamp MC, Boot HJ, Koopmans MP; Medical Microbiological Laboratories and Municipal Health Services.

PLoS One. 2016 Apr 28;11(4):e0154977. doi: 10.1371/journal.pone.0154977. eCollection 2016.

22.

Genetic Diversity in the Major Capsid L1 Protein of HPV-16 and HPV-18 in the Netherlands.

King AJ, Sonsma JA, Vriend HJ, van der Sande MA, Feltkamp MC, Boot HJ, Koopmans MP; Medical Microbiological Laboratories and Municipal Health Services.

PLoS One. 2016 Apr 12;11(4):e0152782. doi: 10.1371/journal.pone.0152782. eCollection 2016. Erratum in: PLoS One. 2016;11(4):e0154977.

23.

Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.

Meulendijks D, Beerepoot LV, Boot H, de Groot JW, Los M, Boers JE, Vanhoutvin SA, Polee MB, Beeker A, Portielje JE, de Jong RS, Goey SH, Kuiper M, Sikorska K, Beijnen JH, Tesselaar ME, Schellens JH, Cats A.

Invest New Drugs. 2016 Feb;34(1):119-28. doi: 10.1007/s10637-015-0309-4. Epub 2015 Dec 8.

PMID:
26643663
24.

Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.

Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, Smits PH, Rosing H, Mandigers CM, Soesan M, Beijnen JH, Schellens JH.

J Clin Oncol. 2016 Jan 20;34(3):227-34. doi: 10.1200/JCO.2015.63.1325. Epub 2015 Nov 16.

PMID:
26573078
25.

[Peritonitis carcinomatosa from colorectal carcinoma: new treatment options].

Vervaal VJ, De Hingh IH, Boot H.

Ned Tijdschr Geneeskd. 2015;159:A9319. Review. Dutch.

PMID:
26556491
26.

Biobanking of fresh-frozen endoscopic biopsy specimens from esophageal adenocarcinoma.

Stiekema J, Cats A, Boot H, Langers AM, Balague Ponz O, van Velthuysen ML, Braaf LM, Nieuwland M, van Sandick JW.

Dis Esophagus. 2016 Nov;29(8):1100-1106. doi: 10.1111/dote.12430. Epub 2015 Nov 6.

PMID:
26541751
27.

Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.

Deenen MJ, Meulendijks D, Boot H, Legdeur MC, Beijnen JH, Schellens JH, Cats A.

Cancer Chemother Pharmacol. 2015 Dec;76(6):1285-95. doi: 10.1007/s00280-015-2872-y. Epub 2015 Oct 23.

PMID:
26499900
28.

Radiation-induced dose-dependent changes of the spleen following postoperative chemoradiotherapy for gastric cancer.

Trip AK, Sikorska K, van Sandick JW, Heeg M, Cats A, Boot H, Jansen EP, Verheij M.

Radiother Oncol. 2015 Aug;116(2):239-44. doi: 10.1016/j.radonc.2015.07.036. Epub 2015 Aug 4.

PMID:
26253953
29.

Selection of chemotherapy for hyperthermic intraperitoneal use in gastric cancer.

Braam HJ, Schellens JH, Boot H, van Sandick JW, Knibbe CA, Boerma D, van Ramshorst B.

Crit Rev Oncol Hematol. 2015 Sep;95(3):282-96. doi: 10.1016/j.critrevonc.2015.04.004. Epub 2015 Apr 17. Review.

PMID:
25921419
30.

Recent trends and predictors of multimodality treatment for oesophageal, oesophagogastric junction, and gastric cancer: A Dutch cohort-study.

Trip AK, Stiekema J, Visser O, Dikken JL, Cats A, Boot H, van Sandick JW, Jansen EP, Verheij M.

Acta Oncol. 2015 Nov;54(10):1754-62. doi: 10.3109/0284186X.2015.1009638. Epub 2015 Mar 23.

PMID:
25797568
31.

Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.

Joerger M, Huitema AD, Boot H, Cats A, Doodeman VD, Smits PH, Vainchtein L, Rosing H, Meijerman I, Zueger M, Meulendijks D, Cerny TD, Beijnen JH, Schellens JH.

Cancer Chemother Pharmacol. 2015 Apr;75(4):763-72. doi: 10.1007/s00280-015-2698-7. Epub 2015 Feb 13.

PMID:
25677447
32.

Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.

Stiekema A, Boldingh QJ, Korse CM, van der Noort V, Boot H, van Driel WJ, Kenter GG, Lok CA.

Gynecol Oncol. 2015 Mar;136(3):562-6. doi: 10.1016/j.ygyno.2014.12.037. Epub 2015 Jan 2.

PMID:
25560808
33.

HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison.

Koopman T, Smits MM, Louwen M, Hage M, Boot H, Imholz AL.

J Cancer Res Clin Oncol. 2015 Aug;141(8):1343-51. doi: 10.1007/s00432-014-1900-3. Epub 2014 Dec 28.

PMID:
25544671
34.

A new fully covered metal stent with anti-migration features for the treatment of malignant dysphagia.

Walter D, van den Berg MW, van Hooft JE, Boot H, Scheffer RC, Vleggaar FP, Siersema PD.

Endoscopy. 2014 Dec;46(12):1101-5. doi: 10.1055/s-0034-1377632. Epub 2014 Sep 30.

PMID:
25268307
35.

IMRT limits nephrotoxicity after chemoradiotherapy for gastric cancer.

Trip AK, Nijkamp J, van Tinteren H, Cats A, Boot H, Jansen EP, Verheij M.

Radiother Oncol. 2014 Aug;112(2):289-94. doi: 10.1016/j.radonc.2014.08.039. Epub 2014 Sep 18.

PMID:
25241995
36.

Does adjuvant chemoradiotherapy improve the prognosis of gastric cancer after an r1 resection? Results from a dutch cohort study.

Stiekema J, Trip AK, Jansen EP, Aarts MJ, Boot H, Cats A, Ponz OB, Gradowska PL, Verheij M, van Sandick JW.

Ann Surg Oncol. 2015 Feb;22(2):581-8. doi: 10.1245/s10434-014-4032-8. Epub 2014 Aug 28.

PMID:
25164039
37.

Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer.

Stiekema J, Vermeulen D, Vegt E, Voncken FE, Aleman BM, Sanders J, Boot H, van Sandick JW.

Clin Nucl Med. 2014 Oct;39(10):862-7. doi: 10.1097/RLU.0000000000000517.

PMID:
25140549
38.

Six-month incidence and persistence of oral HPV infection in HIV-negative and HIV-infected men who have sex with men.

Mooij SH, Boot HJ, Speksnijder AG, Meijer CJ, King AJ, Verhagen DW, de Vries HJ, Quint WG, Molijn A, de Koning MN, van der Sande MA, van der Loeff MF.

PLoS One. 2014 Jun 4;9(6):e98955. doi: 10.1371/journal.pone.0098955. eCollection 2014.

39.

Smoking and older age associated with mumps in an outbreak in a group of highly-vaccinated individuals attending a youth club party, the Netherlands, 2012.

Ladbury G, Ostendorf S, Waegemaekers T, van Binnendijk R, Boot H, Hahne S.

Euro Surveill. 2014 Apr 24;19(16):20776.

40.

Perioperative systemic chemotherapy in peritoneal carcinomatosis of lymph node positive colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Kuijpers AM, Mehta AM, Boot H, van Leerdam ME, Hauptmann M, Aalbers AG, Verwaal VJ.

Ann Oncol. 2014 Apr;25(4):864-9. doi: 10.1093/annonc/mdu031.

PMID:
24667719
41.

Treatment of ovarian metastases of colorectal and appendiceal carcinoma in the era of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Kuijpers AM, Mehta AM, Aalbers AG, van Driel WJ, Boot H, Verwaal VJ.

Eur J Surg Oncol. 2014 Aug;40(8):937-42. doi: 10.1016/j.ejso.2014.02.238. Epub 2014 Feb 28.

PMID:
24630923
42.

A prospective pilot study to assess neoadjuvant chemotherapy for unresectable peritoneal carcinomatosis from colorectal cancer.

Hompes D, Aalbers A, Boot H, van Velthuysen ML, Vogel W, Prevoo W, van Tinteren H, Verwaal V.

Colorectal Dis. 2014 Aug;16(8):O264-72. doi: 10.1111/codi.12560.

PMID:
24433532
43.

Performance of a nomogram predicting disease-specific survival after an R0 resection for gastric cancer in patients receiving postoperative chemoradiation therapy.

Dikken JL, Coit DG, Baser RE, Gönen M, Goodman KA, Brennan MF, Jansen EP, Boot H, van de Velde CJ, Cats A, Verheij M.

Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):624-9. doi: 10.1016/j.ijrobp.2013.11.213. Epub 2014 Jan 7.

PMID:
24411620
44.

Oral human papillomavirus infection in HIV-negative and HIV-infected MSM.

Mooij SH, Boot HJ, Speksnijder AG, Stolte IG, Meijer CJ, Snijders PJ, Verhagen DW, King AJ, de Vries HJ, Quint WG, van der Sande MA, Schim van der Loeff MF.

AIDS. 2013 Aug 24;27(13):2117-28. doi: 10.1097/QAD.0b013e328362395c.

PMID:
24384590
45.

The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy.

Stiekema J, Trip AK, Jansen EP, Boot H, Cats A, Ponz OB, Verheij M, van Sandick JW.

Ann Surg Oncol. 2014 Apr;21(4):1107-14. doi: 10.1245/s10434-013-3397-4. Epub 2013 Dec 4.

PMID:
24306660
46.

Varicella zoster virus infection occurs at a relatively young age in The Netherlands.

van Lier A, Smits G, Mollema L, Waaijenborg S, Berbers G, van der Klis F, Boot H, Wallinga J, de Melker H.

Vaccine. 2013 Oct 17;31(44):5127-33. doi: 10.1016/j.vaccine.2013.08.029. Epub 2013 Aug 22.

PMID:
23973248
47.

Selective hepatitis B virus vaccination has reduced hepatitis B virus transmission in the Netherlands.

Hahné S, van Houdt R, Koedijk F, van Ballegooijen M, Cremer J, Bruisten S, Coutinho R, Boot H.

PLoS One. 2013 Jul 29;8(7):e67866. doi: 10.1371/journal.pone.0067866. Print 2013.

48.

Patterns of human papillomavirus DNA and antibody positivity in young males and females, suggesting a site-specific natural course of infection.

Vriend HJ, Bogaards JA, van der Klis FR, Scherpenisse M, Boot HJ, King AJ, van der Sande MA; Medical Microbiological Laboratories, Municipal Health Services.

PLoS One. 2013 Apr 23;8(4):e60696. doi: 10.1371/journal.pone.0060696. Print 2013.

49.

Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.

Deenen MJ, Dewit L, Boot H, Beijnen JH, Schellens JH, Cats A.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):e201-7. doi: 10.1016/j.ijrobp.2012.12.008.

PMID:
23517808
50.

Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach?

Stiekema J, Cats A, Kuijpers A, van Coevorden F, Boot H, Jansen EP, Verheij M, Balague Ponz O, Hauptmann M, van Sandick JW.

Eur J Surg Oncol. 2013 Jul;39(7):686-93. doi: 10.1016/j.ejso.2013.02.026. Epub 2013 Mar 15.

PMID:
23498364

Supplemental Content

Support Center